Name | Title | Contact Details |
---|
KC Pharmaceuticals is a Pomona, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Absolute Biotech is a company that specializes in antibody reagents, kits, and services, adding value to existing antibodies through annotation, validation, sequencing, engineering, and recombinant manufacturing.
ReCept Pharmacy is a Fort Worth, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Akcea Therapeutics is a development and commercialization company focused on helping patients with serious diseases. Our priority is to drive clinical program execution, understand patient and physician needs, prepare the market, create market access, and commercialize our products on a global basis. We are driven by knowing that patients depend on us. An affiliate of Ionis Pharmaceuticals and based in Kendall Square, Cambridge, Massachusetts, Akcea was founded with a robust portfolio of development-stage drugs covering multiple targets and disease states using advanced antisense therapeutics. Akcea is derived from the Greek word for value and worth. Something that has akcea (αξία) is not common, but precious and rare. Our name supports the value we are creating for physicians, patients and their families, and other key stakeholders as we seek to commercialize a robust portfolio of development-stage, advanced, antisense therapies for serious cardiometabolic lipid disorders. Our immediate focus is to drive our clinical programs forward through development to commercialization while building on the Isis standards of excellence.
Longboard Pharmaceuticals, Inc. (Longboard) is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Longboard was formed in January 2020 by Arena Pharmaceuticals, Inc. (Arena) to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). Longboard`s small molecule product candidates were discovered out of the same platform at Arena that represents a culmination of more than 20 years of GPCR research. Longboard is evaluating LP352, an oral, centrally acting, 5-hydroxytryptamine 2c receptor subtype superagonist, in development for the potential treatment of developmental and epileptic encephalopathies. Longboard is also evaluating LP143, a centrally acting, full cannabinoid type 2 receptor agonist, in development for the potential treatment of neurodegenerative diseases associated with neuroinflammation caused by microglial activation, and LP659, a centrally acting, sphingosine-1-phosphate receptor subtypes 1 and 5 modulator, in development for the potential treatment of central nervous system neuroinflammatory diseases.